ChromoGenics Q1 2024: Continued tough market hit topline and negative operating cash flow are concerning. - Redeye

Redeye comments on ChromoGenics Q1 2024 report. Sales came in lower than our estimate due to the continued weak sentiment in the construction sector impacting sales. Operating cash flows were SEK-12m in the quarter, and with a cash position of SEK2.6m, it looks like another capital injection is needed before the end of 2024.

Länk till analysen i sin helhet: https://www.redeye.se/research/994416/chromogenics-q1-2024-continued-tough-market-hit-topline-and-negative-operating-cash-flow-are-concerning?utm_source=finwire&utm_medium=RSS